Astellas PharmaALPMF -6.90%73 Buyback Yield % is 0.02 as of Jul. 01, 2026, which is 99% below its 10-year median of 1.70. GuruFocus rates ALPMF with a GF Score™ of 73/100 and a GF Value™ of $14.80 (Fairly Valued). The stock has 4 warning signs investors should review. Among 293 Drug Manufacturers companies, Astellas Pharma ranks better than 68.6% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Astellas Pharma's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ALPMF vs LLY, JNJ, ABBV: Buyback Yield % Comparison
For the Drug Manufacturers - General subindustry, Astellas Pharma's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Astellas Pharma Buyback Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Astellas Pharma's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Astellas Pharma's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Astellas Pharma (ALPMF) has a Buyback Yield % of 0.02 as of Jul. 01, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Astellas Pharma and its competitors. This is 99% below median its historical median of 1.70. Over the past decade, Astellas Pharma's Buyback Yield % has ranged from 0.02 to 5.96. According to the industry distribution chart, Astellas Pharma ranks #92 out of 293 companies in the Drug Manufacturers industry, placing it in the top 31.4%.
Is Astellas Pharma's Buyback Yield % too high?
Astellas Pharma's current Buyback Yield % of 0.02 is 99% below median its 10-year median of 1.70. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 5.96. Based on the distribution chart, Astellas Pharma ranks #92 out of 293 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Astellas Pharma has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Astellas Pharma's Buyback Yield % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Astellas Pharma ranks #92 out of 293 companies for Buyback Yield %. This puts Astellas Pharma in the upper half of its industry. Historically, Astellas Pharma's own Buyback Yield % has ranged from 0.02 to 5.96 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Astellas Pharma and its competitors. Astellas Pharma's current Buyback Yield % is 0.02, which is 99% below median its own 10-year median of 1.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Astellas Pharma stock overvalued right now?
Based on GuruFocus' analysis, Astellas Pharma (ALPMF) is currently considered Fairly Valued. The stock's GF Value™ is $14.80, compared to a current price of $13.50 — trading 8.8% below its estimated fair value. The current Buyback Yield % is 0.02, which is 99% below median its 10-year median of 1.70. Astellas Pharma's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Astellas Pharma (ALPMF), the current Buyback Yield % is 0.02 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Astellas Pharma (ALPMF) Overvalued in 2026?
Based on GuruFocus' analysis, Astellas Pharma stock appears to be undervalued.
The current stock price of $13.50 is trading 8.8% below its estimated GF Value™ of $14.80.
GuruFocus considers Astellas Pharma to be Fairly Valued.
Key valuation signals for ALPMF:
Buyback Yield %: 0.02 (99% below median its 10-year median of 1.70)
GF Value™: $14.80 vs. price of $13.50 (8.8% below fair value)
No single metric tells the full story. See the ALPMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Astellas Pharma Inc is a specialty international pharmaceutical company. The company focuses on accelerating the discovery, development, and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.
73GF Score
Get the complete analysis for ALPMF
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALPMF has been successfully added to your 
